Summary
Shares in drugs giant AstraZeneca look set for a bumpy ride in the next fortnight, with positive news expected for cholesterol fighter Cres-tor but experimental heart drug AGI-1067 widely tipped to fail in a key study.
Clinical trial results on both products are due to be released at the American College of Cardiology annual meeting in New Orleans on March 25 and 27 respectively.See the full content of this document
Extract
Astrazeneca Set for Bumpy Ride
"If it plays out the way the market is expecting, I think overall it will have a negative impact on the stock," UBS Pharmaceuticals analyst David Beadl...
See the full content of this document
Sponsored links
